SCHEMBL30133703

SCHEMBL30133703

CC[C@@H](NC(=O)OC(C)(C)C)c1cc[nH]n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
PTPRB P23467 1/20 0.38
CTSS P25774 2/20 0.38
CTSK P43235 2/20 0.38
MAPK1 P28482 1/20 0.38
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
SYK P43405 1/20 0.38
AAK1 Q2M2I8 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29168235 1.00 ALDH1A1 (0.40) ALDH1A1PTPRBCTSSCTSKMAPK1
SCHEMBL29168266 1.00 ALDH1A1 (0.40) ALDH1A1PTPRBCTSSCTSKMAPK1
SCHEMBL29168123 0.86 MEN1 (0.38) ALDH1A1PTPRBCTSSCTSKPPARG
SCHEMBL31622069 0.84 MAPT (0.40) ALDH1A1PTPRBCTSSCTSKMAPK1
SCHEMBL20204212 0.83 ALDH1A1 (0.53) ALDH1A1PTPRBCTSSCTSKMAPK1
SCHEMBL29168092 0.81 KMT2A (0.44) ALDH1A1CTSKPPARGPPARAMEN1
SCHEMBL29168193 0.81 KMT2A (0.44) ALDH1A1CTSKPPARGPPARAMEN1
SCHEMBL29168192 0.81 KMT2A (0.44) ALDH1A1CTSKPPARGPPARAMEN1
SCHEMBL29168052 0.80 SSTR3 (0.41) ALDH1A1CTSSCTSKMAPK1MEN1
SCHEMBL29168018 0.79 TRPA1 (0.41) ALDH1A1MAPK1PPARGMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2024-09-12 US disclosed
EP-4352049-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Avelos Therapeutics Inc. (KR) 2024-04-17 EP disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 CN disclosed
WO-2022260441-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2022-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS MAST1, MAST3, MAST4 ALDH1A1 4232/4885PTPRB 1672/4885CTSS 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.